Brielle Benyon, Assistant Managing Editor for CURE®, has been with MJH Life Sciences since 2016. She has served as an editor on both CURE and its sister publication, Oncology Nursing News. Brielle is a graduate from The College of New Jersey. Outside of work, she enjoys spending time with family and friends, CrossFit and wishing she had the grace and confidence of her toddler-aged daughter.
Follow Brielle on Twitter @Brielle_Benyon.
Tina Turner’s Son Dies of Cancer, NFL Team Honors Group’s $5.6 Million Fundraising Effort and More
December 16th 2022From Tina Turner’s son, Ronnie, dying of cancer to the Miami Dolphins honoring a group of people who raised over $5 million for oncology care and research, here is what’s happening in the cancer space this week.
Educated Patient® MPN Summit First-line Treatment in Myelofibrosis Presentation: November 19, 2022
December 16th 2022Watch to Dr. Naveen Pemmaraju, from The University of Texas MD Anderson Cancer Center, discuss frontline treatment options for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.
Researchers Hope a New Drug Can Help Overcome Immunotherapy Resistance in Metastatic Cancers
December 2nd 2022A recently launched clinical trial of NTX1088 will determine if the novel drug can help overcome immune checkpoint inhibition resistance in patients with locally advanced or metastatic solid tumors.
High Sugar Intake May Lead to Premature Aging in Childhood Cancer Survivors
November 22nd 2022Childhood cancer survivors who had high daily sugar intake — especially when it came to sweetened beverages — had an increased risk of premature aging-related health complications, according to recent research.
‘Star Trek’ Actors Team Up for Cancer Research, Michelle Obama Meets a Sarcoma Survivor and More
November 18th 2022From “Star Trek” actors supporting the Pancreatic Cancer Action Network to Michelle Obama meeting with a sarcoma survivor and an update on Jane Fonda’s cancer, here’s what’s happening in the cancer space this week.
Novel Drug-Chemo Combination Improves Outcomes for Advanced Gastric Cancers
November 18th 2022Zolbetuximab plus the chemotherapy regimen mFOLFOX6 improved progression-free survival and overall survival in certain patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.